Peer-reviewed veterinary case report
Toceranib phosphate treatment results for bladder tumors in 37 dogs
By Gustafson, Tanya Lynn & Biller, Barbara·Published in Journal of the American Animal Hospital Association·2019·Colorado State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
- Species:
- dog
Plain-English summary
A group of 37 dogs with bladder tumors called transitional cell carcinoma (TCC) were treated with a medication called toceranib phosphate. While most dogs tolerated the treatment well, some experienced worsening kidney function. About 7% of the dogs showed improvement in their tumors, and 80% had stable disease for an average of about 4 months. The average survival time after starting treatment was about 5 months. This suggests that toceranib may help manage TCC in dogs, but it's important for vets to monitor kidney health during treatment.
People also search for: dog bladder tumor treatment · transitional cell carcinoma in dogs · toceranib phosphate side effects · dog kidney function monitoring
Abstract
Transitional cell carcinoma (TCC) is a locally aggressive tumor in dogs with low-to-moderate responses to traditional chemotherapeutic agents. Toceranib (TOC) phosphate represents a novel agent for the treatment of canine TCC. Thirty-seven dogs were identified who had received TOC for bladder tumor treatment. The TOC was generally well tolerated, although 56% of dogs had progression of azotemia while receiving TOC. A partial response to TOC was observed in 6.7% of dogs, and 80% of dogs had stable disease for a median duration of 128.5 days. Median time to progression was 96 days, and median survival time after the start of TOC was 149 days. There were no significant variables influencing time to progression or survival time in this group of dogs. This retrospective study suggests that TOC may be useful for the treatment of TCC. However, careful monitoring of renal function is recommended in patients with bladder tumors receiving TOC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31433219/